Treatment of ungual and subungual diseases

• US 20040176312A1
• Filed: 02/02/2004
• Published: 09/09/2004
• Est. Priority Date: 04/23/2002
• Status: Active Grant

• Current Assignee: NUCRYST Pharmaceuticals Corp. (The Westaim Corporation)
• Original Assignee: NUCRYST Pharmaceuticals Corp. (The Westaim Corporation)
• Inventors: Gillis, Scott H.
• Granted Patent: US 7,201,925 B2
• Time in Patent Office: Days
• US Class Current: 514/36
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 33/38 Silver; Compounds thereof
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 47/38 Cellulose; Derivatives thereof
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 17/12 Keratolytics, e.g. wart or anti-corn preparations
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/10 Antimycotics

Abstract

The treatment of ungual and subungual diseases is disclosed.

Claims

1. A method for the treatment or prophylaxis of an ungual or subungual disease of a subject, the method comprising:

using a needleless injector to deliver a compound to an area of the subject associated with the disease, the compound being effective in the treatment of the disease.

2. The method of claim 1, wherein the compound comprises a metal-containing material.

3. The method of claim 1, wherein the compound comprises an anti-fungal compound.

4. The method of claim 1, wherein the compound is selected from the group consisting of griseofulvin, terbinafine, citopirox, itraconazole, ketoconazole and combinations thereof.

5. The method of claim 4, wherein the disease is selected from the group consisting of onychomycosis, tinea unguim infection, and combinations thereof.

6. The method of claim 1, wherein the disease is selected from the group consisting of onychomycosis, tinea unguim infection, psoriasis of the unguis, eczema of the unguis, lichen planus of the unguis, viral warts of the unguis and combinations thereof.

7. The method of claim 1, wherein the disease is a subungual disease.

8. The method of claim 1, wherein the disease is an ungual disease.

9. The method of claim 1, wherein the area of the subject comprises an unguis.

10. The method of claim 9, wherein the subject is a human and the unguis is a toe nail.

11. The method of claim 9, wherein the subject is a human and the unguis is a finger nail.

12. The method of claim 1, wherein the area of the subject comprises tissue adjacent an unguis of the subject.

13. The method of claim 12, wherein the tissue adjacent the unguis of the subject comprises skin.

14. The method of claim 1, wherein the needleless injector delivers the compound into an unguis of the subject.

15. The method of claim 14, wherein the needleless injector delivers the compound through the unguis of the subject.

16. The method of claim 1, wherein the needleless injector delivers the compound through an unguis of the subject.

17. The method of claim 1, wherein the needleless injector delivers the compound into tissue adjacent an unguis of the subject.

18. The method of claim 17, wherein the tissue adjacent the unguis of the subject comprises skin.

19. The method of claim 17, wherein the needleless injector delivers the compound through the tissue adjacent the unguis.

20. The method of claim 1, wherein the needleless injector delivers the compound through tissue adjacent an unguis of the subject.

21. The method of claim 20, wherein the tissue adjacent the unguis of the subject comprises skin.

22. The method of claim 1, wherein the needleless injector delivers the compound into an unguis of the subject and into tissue adjacent the unguis of the subject.

23. The method of claim 22, wherein the needleless injector delivers the compound through the unguis of the subject.

24. The method of claim 23, wherein the needleless injector delivers the compound through tissue adjacent an unguis of the subject.

25. The method of claim 22, wherein the needleless injector delivers the compound through tissue adjacent an unguis of the subject.

26. The method of claim 1, wherein the subject is a human.

27. A method for the treatment or prophylaxis of an ungual or subungual disease of a subject, the method comprising:

using iontophoresis to deliver a compound to an area of the subject associated with the disease, the compound being effective in the treatment of the disease.

28. The method of claim 27, wherein the compound comprises a metal-containing material.

29. The method of claim 27, wherein the compound comprises an anti-fungal compound.

30. The method of claim 27, wherein the compound is selected from the group consisting of griseofulvin, terbinafine, citopirox, itraconazole, ketoconazole and combinations thereof.

31. The method of claim 30, wherein the disease is selected from the group consisting of onychomycosis, tinea unguim infection, and combinations thereof.

32. The method of claim 27, wherein the disease is selected from the group consisting of onychomycosis, tinea unguim infection, psoriasis of the unguis, eczema of the unguis, lichen planus of the unguis, viral warts of the unguis and combinations thereof.

33. The method of claim 27, wherein the disease is a subungual disease.

34. The method of claim 27, wherein the disease is an ungual disease.

35. The method of claim 27, wherein the area of the subject comprises an unguis.

36. The method of claim 35, wherein the subject is a human and the unguis is a toe nail.

37. The method of claim 35, wherein the subject is a human and the unguis is a finger nail.

38. The method of claim 27, wherein the area of the subject comprises tissue adjacent an unguis of the subject.

39. The method of claim 38, wherein the tissue adjacent the unguis of the subject comprises skin.

40. The method of claim 27, wherein iontophoresis delivers the compound into an unguis of the subject.

41. The method of claim 40, wherein iontophoresis delivers the compound through the unguis of the subject.

42. The method of claim 27, wherein iontophoresis delivers the compound through an unguis of the subject.

43. The method of claim 27, wherein iontophoresis the compound into tissue adjacent an unguis of the subject.

44. The method of claim 43, wherein the tissue adjacent the unguis of the subject comprises skin.

45. The method of claim 43, wherein iontophoresis delivers the compound through the tissue adjacent the unguis.

46. The method of claim 27, wherein iontophoresis the compound through tissue adjacent an unguis of the subject.

47. The method of claim 46, wherein the tissue adjacent the unguis of the subject comprises skin.

48. The method of claim 27, wherein iontophoresis delivers the compound into an unguis of the subject and into tissue adjacent the unguis of the subject.

49. The method of claim 48, wherein iontophoresis delivers the compound through the unguis of the subject.

50. The method of claim 49, wherein iontophoresis delivers the compound through tissue adjacent an unguis of the subject.

51. The method of claim 48, wherein iontophoresis delivers the compound through tissue adjacent an unguis of the subject.

52. The method of claim 27, wherein the subject is a human.